Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.

Huijian Xie,Yan He,Shaoyan Zhang,Yanbo Jiang,Yan An,Xinyuan Qu,Mingzhi Zhang,Daoyi Huang,Xinya Wang

doi:10.1155/2020/3284769

Abstract

Up to date, human urotensin II (UII) is the most potent vasoconstrictor in mammalian animals. To explore whether UII played an important role in the development of hypertension, we conducted a prospective study in Changshu city, China. The baseline investigation was carried out in 2007, and the first follow-up investigation was conducted in 2013. From the participants, we randomly obtained 2000 normotensive subjects aged 40 years and older without any severe disease at baseline and examined plasma UII and endothelin-1 (ET-1) with their blood samples at baseline. Logistic models were used to analyze the association between baseline UII, baseline ET-1, and newly occurring hypertension. In 1,819 subjects with complete data, 723 subjects developed into hypertensive in about five years. After adjusting some potential confounders, the odds ratio (95% confidence interval) for risk of hypertension comparing the highest with the lowest quartile of baseline UII was 0.888 (0.689–1.144). The role of UII in the development of hypertension was not found in the current study; therefore, further research studies should be conducted to explore the relationship between UII and hypertension.

Highlights

Hypertension, the leading cause of morbidity and mortality of cardiovascular diseases (CVD), has become a global public health challenge [1]
E average age at baseline was 51.6. ere was no difference in levels of most characteristics except ET-1 at baseline among the quartile groups according to urotensin II (UII) levels. e general characteristics of the participants at baseline are presented in Table 1 in detail
Levels of ET-1 at baseline were significantly different between the new cases of hypertension and the normotensive participants, while levels of UII were not. e other general characteristics at baseline were compared between the new cases of hypertension and the normotensive participants

Summary

Introduction

Hypertension, the leading cause of morbidity and mortality of cardiovascular diseases (CVD), has become a global public health challenge [1]. A lot of studies have been conducted to explore the risk factors of hypertension, the etiology of hypertension is still obscure. Urotensin II (UII) is a cyclic peptide initially isolated from the urophysis of the goby fish based on its potent vasoconstrictor effect [2], and it was cloned from humans. UII is considered as the most potent vasoconstrictor, and its vasoactive activity is even more potent than endothelin-1 (ET-1) [3, 4]. Because of the inconsistent results of the published studies [5,6,7,8], the association between. UII and hypertension has not been confirmed yet. Most of these studies are case-control studies, which are weak to explore the causal relationship between UII and hypertension

Methods

Results

Conclusion